AbbVie Inc (ABBV) stock price

AbbVie Inc (ABBV) is a Healthcare · Drug Manufacturers - General company listed on NYSE. Price $263.96 (-0.02%), Market cap $378.98B, P/E ratio 105.15, 52-week low–high $182.31 ~ $244.38.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Ju

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for AbbVie Inc are updated in real time on BlackAll Trade.

AbbVie Inc financial summary

Analyst outlook

Key ratios · profitability · growth

AbbVie Inc investor discussion

5 recent posts · 4 bullish · 0 bearish · 1 neutral.

Frequently asked questions

What is the current AbbVie Inc (ABBV) stock price?

AbbVie Inc trades at $263.96 (-0.02%). Real-time quotes and charts are available on BlackAll Trade.

What is the AbbVie Inc (ABBV) market cap?

AbbVie Inc has a market cap of about $378.98B. Its P/E ratio is 105.15.

What does AbbVie Inc (ABBV) do?

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyr